Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A Bernard-Soulier syndrome characterized by autosomal dominant inheritance of mild to moderate bleeding tendency, thrombocytopenia, and an increased mean platelet size that has material basis in heterozygous mutations in the GP1BA gene on chromosome 17p.
Features include always present findings: Menorrhagia, Increased mean platelet volume, Impaired ristocetin-induced platelet aggregation, and Prolonged bleeding after dental extraction and others; and common findings: Epistaxis. 15 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 9 | Increased mean platelet volume, Impaired collagen-related peptide-induced platelet aggregation, Impaired ristocetin-induced platelet aggregation |
GP1BA encodes glycoprotein Ib platelet subunit alpha (652 aa). GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium Highest expression in Skin Sun Exposed Lower leg (4.2 TPM) and Skin Not Sun Exposed Suprapubic (4.0 TPM).
Bernard-Soulier syndrome, type A2, autosomal dominant is associated with mutations in the GP1BA gene on chromosome 17.
The GP1BA protein participates in GP1BA variant:GP1BB:GP9, GP1BA variant:GP1BB:GP9:GP5, and RUNX1:CBFB:SIN3A,(SIN3B):PRMT6:HDAC1:GP1BA gene:H3K4me2-Nucleosome pathways.
GP1BA is classified as a druggable target (Cell Surface, Druggable Genome, and External Side Of Plasma Membrane categories) with score 4.7.
Genetic testing for GP1BA is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 5 always present features, 1 common feature.
No clinical trials have been registered for Bernard-Soulier syndrome, type A2, autosomal dominant.
2 publications have been identified in PubMed for Bernard-Soulier syndrome, type A2, autosomal dominant. Research spans Review / Meta-Analysis (100%).
Safdari SM (2025). [PMID: 41316200](https://pubmed.ncbi.nlm.nih.gov/41316200/). *Thromb J*. [Review / Meta-Analysis]
Sánchez-Fuentes A (2025). [PMID: 40563486](https://pubmed.ncbi.nlm.nih.gov/40563486/). *Biomolecules*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Bernard-Soulier syndrome, type A2, autosomal dominant
Digestive system | 1 | Enlarged spleen (splenomegaly) |
AI-curated news mentioning Bernard-Soulier syndrome, type A2, autosomal dominant
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.